ACT AlzChem Group

DGAP-News: AlzChem Group AG: Consistent growth course supported by Annual General Meeting

DGAP-News: AlzChem Group AG / Key word(s): AGM/EGM
AlzChem Group AG: Consistent growth course supported by Annual General Meeting

12.05.2021 / 18:10
The issuer is solely responsible for the content of this announcement.


- Dividend of EUR 0.77 per share resolved, corresponds to 40% of consolidated net income
- Strong start to fiscal year 202
- Achievement of full-year guidance expected at upper end

Trostberg, May 12, 2021 - "I am very pleased with the vote of confidence by our shareholders to both support our successful growth course and confirm our dividend policy through the resolutions at today's virtual Annual General Meeting. We will continue to implement exciting projects in 2021 that will allow our company to grow further in terms of sales and profits," explained Andreas Niedermaier, CEO of AlzChem Group AG. He cited a number of examples of this: "Before the end of this year, we will launch EMINEX(R), a product that can raise climate protection in agriculture to a new level globally. In the case of our important product of the future, Creamino(R), we will be judged by the success of our new sales strategy in 2021, because the market is beginning to turn around with the pandemic possibly subsiding, and there are clear indicators that we will soon be able to show significantly more dynamic growth rates again with correspondingly positive margin effects. A third example is our expanded nitrile capacities, which we have expanded by a further 50% through investments of around EUR 12 million and which will be fully available before the end of the second quarter of 2021. This could generate additional annual sales of EUR 10 to 20 million -depending on the product mix. And this product mix has plenty to offer: intermediates for the pharmaceutical and biocide industries, environmentally friendly pigments in automotive coatings, and UV absorbers in sun creams will noticeably support our growth," says Niedermaier.

This year, AlzChem Group AG aims to grow sales to up to EUR 400 million (2020: EUR 379.3 million) and EBITDA to a stable to slightly increasing result of up to EUR 57 million (2020: EUR 53.8 million). Following the very good performance of the financial year to date, the forecast is expected to be achieved rather at the upper end.

The Annual General Meeting 2021 of AlzChem Group AG today resolved to distribute a dividend of EUR 0.77 per share to be paid on May 18, 2021. This corresponds to a distribution volume of EUR 7.8 million, or just under 40% of the consolidated net income of EUR 19.9 million achieved in 2020. AlzChem Group AG's dividend policy is to distribute between 30% and 50% of net income each year.

All other resolutions at today's Annual General Meeting were also passed by a large majority, including the discharge of the Management Board and Supervisory Board, the election of the auditor, the approval of the remuneration system for the Management Board and the remuneration of the Supervisory Board members.

The voting results of the Annual General Meeting can be viewed on the website at .

About AlzChem

AlzChem is a globally active specialty chemicals company that is predominantly among the market leaders in its fields of activity. AlzChem benefits in particular from the three very different global megatrends of sustainability, population growth and healthy aging. AlzChem products offer attractive solutions in a wide range of applications.

The company sees interesting growth prospects for itself above all in the fields of human and animal nutrition, pharmaceuticals, agriculture, fine chemicals, metallurgy and renewable energies. The broad product range includes, for example, dietary supplements, plant growth regulators and precursors for corona tests.

The company employs around 1,630 people at four production sites in Germany and Sweden, and at two sales companies in the USA and China. In 2020, AlzChem generated consolidated sales of around EUR 379 million and EBITDA of around EUR 53.8 million.

Contact:
Sabine Sieber
Head of Investor Relations & Communications


12.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


Language: English
Company: AlzChem Group AG
Dr.-Albert-Frank-Str. 32
83308 Trostberg
Germany
Phone:
Fax:
E-mail:
Internet:
ISIN: DE000A2YNT30
WKN: A2YNT3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart
EQS News ID: 1196083

 
End of News DGAP News Service

1196083  12.05.2021 

fncls.ssp?fn=show_t_gif&application_id=1196083&application_name=news&site_id=research_pool
EN
12/05/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AlzChem Group

Peter Thilo Hasler
  • Peter Thilo Hasler

Zum Halbjahr neue Höchstwerte bei Umsatz und Marge

Während das Basissegment Basics & Intermediates erwartungsgemäß rückläufig war (H1/2025 Umsatz EUR 78,2 Mio., -14,2% YoY), verzeichnete das margenträchtige Segment Specialty Chemicals im ersten Halbjahr 2025 ein Umsatzplus von 8,9% auf EUR 194,6 Mio. – getragen von einem Nachfrageaufschwung im Bereich Custom Manufacturing sowie einem weiterhin starken Geschäft mit Creapure im Bereich Human Nutrition. Der Umsatzanteil des Segments liegt mittlerweile bei 67,7% – Tendenz steigend und ist damit nach...

Peter Thilo Hasler
  • Peter Thilo Hasler

Weiterhin mit robustem Gewinnwachstum

Nach wie vor ist die Ertragsentwicklung von Alzchem von konjunkturellen Herausforderungen geprägt, profitiert aber in ungleich stärkerem Maße von der Verschiebung des Umsatz-Mix in das hochmargige Segment Specialty Chemicals. Weil deshalb die vorgelegten Zahlen zum ersten Quartal 2025 erneut über unseren Schätzungen sowie den Consensus-Erwartungen lagen und wir davon ausgehen, dass die höhermargigen Potenziale weiterhin abgeschöpft werden können, heben wir unser aus einem dreiphasigen DCF-Entity...

 PRESS RELEASE

EQS-News: Alzchem Group AG: Bekanntmachung nach Art. 5 der Verordnung...

EQS-News: Alzchem Group AG / Schlagwort(e): Aktienrückkauf/Aktienrückkauf Alzchem Group AG: Bekanntmachung nach Art. 5 der Verordnung (EU) 596/2014 und Art. 2 Abs. 1 der Delegierten Verordnung (EU) 2016/1052 - Zeitweilige Unterbrechung des Aktienrückkaufprogramms 17.03.2025 / 11:38 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Alzchem Group AG   Bekanntmachung nach Art. 5 der Verordnung (EU) 596/2014 und Art. 2 Abs. 1 der Delegierten Verordnung (EU) 2016/1052       Trostberg, 17. März 2025   Zeitweilige Unterbrechung de...

 PRESS RELEASE

EQS-News: Alzchem Group AG: Disclosure according to Article 5 of the ...

EQS-News: Alzchem Group AG / Key word(s): Share Buyback/Share Buyback Alzchem Group AG: Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - Temporary Interruption of Share Repurchase Prog 17.03.2025 / 11:38 CET/CEST The issuer is solely responsible for the content of this announcement. Alzchem Group AG   Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052     Trostberg, March 17, 2025   Temporary Inter...

Peter Thilo Hasler
  • Peter Thilo Hasler

Von hohem Niveau aus weiter aufwärts

Dass Alzchem auch im vierten Quartal 2024 sowohl die eigene Guidance als auch alle Consensus-Prognosen übertraf, kann aus unserer Sicht nicht als Normalität eingestuft werden. Kritisch ließe sich einwenden, dass die Luft angesichts des inzwischen erreichten Margenniveaus dünner wird, doch lässt die anhaltende Verschiebung zum höhermargigen Segment Specialty Chemicals nach unserer Auffassung einen erneuten Margenanstieg und einen damit einhergehenden überproportionalen Ergebnisanstieg auch im Ges...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch